Publications

Annual Report

CTx Annual Report 2014-15

CTx Annual Report 2012-13

Journal Papers

Inhibition of Focal Adhesion Kinase in Combination With Bevacizumab Reduces the Rate of Tumor Revascularization and Increases Survival in a Pre-clinical Model of Basal Breast Cancer 
Falk H, Connor T, Yang H , Loft KJ, Bentley JD, Hattarki MK, Dolezal O, Murphy JM, Monahan BJ,  Peat TS, Thomas T, Baell JB, Parisot JP, Street IP. J. Biomolecular Screening, (2011): 10.1177/1087057111421631

Conf​erence presentations

Potent and selective PRMT5 inhibitors as potential treatment for cancers

Hendrik Falk, Ylva E. Bergman, Scott R. Walker, Stefan E. Sonderegger, Elizabeth Allan, Jonathan B. Baell, Michelle A. Camerino, Loretta Cerruti, Susan A. Charman, Melanie de Silva, Mark Devlin, Olan Dolezal, Richard C. Foitzik, Danny Ganame, Julian Grusovin, Stefan J. Hermans, Catherine F. Hemley, Ian P. Holmes, Wilhelmus J.A. Kersten, H. Rachel Lagiakos, Romina Lessene, Kym Lowes, Gillian E. Lunniss, Benjamin J. Morrow, Anthony Natoli, Michael W. Parker, Jo-Anne Pinson, Thomas S. Peat, Patricia Pilling, Sukhdeep K. Spall, Alex E. Stupple, Yuen T. Tan, Alison Thistlethwaite, Emma Toulmin, Karen L. White, David J. Curtis, Stephen M. Jane, Brendon J. Monahan, Paul A. Stupple, and Ian P. Street.

Poster: American Association for Cancer Research (AACR) Annual Meeting, April 18-22, 2015, Philadelphia, PA, USA


 

Characterization of the novel broad-spectrum kinase inhibitor CTx-0294885 (KiNet-1) as an affinity reagent for mass spectrometry-based kinome profiling. Luxi Zhang, Ian Holmes, Falko Hochgräfe, Scott Walker, Wilco Kersten, Ian Street, Roger J Daly, John Feutrill. Poster: Boston, June 2013


A High Throughput Screening Platform for the Identification of Small Molecule Inhibitors of the Ubiquitin E3 Ligase E6AP I Street, B Monahan, L Allan, P Pilling, T Peat, E Allan, M de Silva, H Falk, P Stupple, K Wolyniec, I Holmes, L Sparrow, S Haupt, A Chan, Y Haupt, K Lackovic. Poster: EACR-22, Barcelona, Spain, July 2012.


Inhibition of Focal Adhesion Kinase in Combination With Bevacizumab Reduces the Rate of Tumor Revascularization and Increases Survival in a Pre-clinical Model of Basal Breast Cancer. I Street, L Allan, R Anderson, Y Bergman, M Camerino, S Charman, N Choi, T Connor, M de Silva, J Doherty, H Falk, R Foitzik, D Ganame, M Gorman, A Gregg, C Hemley, G Holloway, W Kersten, K Lackovic, R Lessene, K Leuchowius, G Lovrecz, G Lunniss, G McArthur, N McKern, B Monahan, B Morrow, A Natoli, M Nikac, P Novello, M Parker, T Peat, C Scott, M Tiong, K Visser, S Walker, H Yang, I Holmes, M Devlin. Poster: EACR-22, Barcelona, Spain, July 2012.


Combination of CTx-0294945 a highly selective inhibitor of focal adhesion kinase with bevacizumab in pre-clinical models of breast cancer. I. Street, M de Sylva, K. Lackovic, D. Ganame, G. Holloway, R. Anderson, G McArthur, A Natoli, J Doherty, H Falk, W Kersten, R Lessene, K Leuchowius, P Novello, H Yang, Y Bergman, M Camerino, S Charman, A Gregg, N Choi, R Foitzik, C Hemley, G Lunniss, M Nikac, S Walker, G Lovrecz, B Monahan, T Peat, C Robinson, C Scott, M Gorman, M Parker, I Holmes, and M Devlin (2012)  Poster: 103rd Annual Meeting of the American Association for Cancer Research, Chicago, USA, Mar 31-Apr 4 2012.


The small molecule Focal Adhesion Kinase (FAK) inhibitor PF-562,271 inhibits tumour growth in an in vivo model of human triple-negative breast cancer and potentiates the effect of docetaxel therapy. Natoli A, Visser K, Lackovic K, Falk H, Choi N, Bergman Y,  Gregg A, Charman S, Anderson R, Devlin M, Holmes I, Street I. Poster: Ludwig Institute for Cancer Research (LICR) Translational Research Conference, Melbourne, Australia, October 2011.


Pharmacokinetic and Pharmacodynamic (PK/PD) analysis of the small molecule Focal Adhesion Kinase (FAK) inhibitor PF-562,271 in an in vivo model of human triple negative breast cancer. Visser K, Natoli A, Lackovic K, Falk H, Choi N, Bergman Y, Gregg A, Charman S, Morrizi J, Steuten J, Doherty J, Anderson R, Devlin M, Holmes I, Street I. Poster: Ludwig Institute For Cancer Research (LICR) Translational Research Conference, Melbourne, Australia, October 2011.


Development of relevant in vitro and in vivo assays for the preclinical assessment of small molecule CSF-1R inhibitors. Doherty J, Alcindor J, Kersten W, Nikolakopoulos G, Loft K, Phillipson L, Swierczak A, Holmes I, Anderson R, Street I. Poster: Ludwig Institute For Cancer Research (LICR) Translational Research Conference, Melbourne, Australia, October 2011.


The Importance of Relevant Bioassays to the Development of Focal Adhesion Kinase InhibitorsVisser K, Connor T, Lackovic K, Devlin M, Falk H, Natoli A, Choi N, Kersten W, Goeminne A, Parisot J, Anderson R, Holmes I, Street I. Joint Metastasis Research Society-AACR Conference in Conjunction with the Tumor Microenvironment Working Group of the AACR, Philadelphia, USA, September 2010